1. Home
  2. NRIX vs CRSR Comparison

NRIX vs CRSR Comparison

Compare NRIX & CRSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • CRSR
  • Stock Information
  • Founded
  • NRIX 2009
  • CRSR 1994
  • Country
  • NRIX United States
  • CRSR United States
  • Employees
  • NRIX N/A
  • CRSR N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • CRSR Computer Manufacturing
  • Sector
  • NRIX Health Care
  • CRSR Technology
  • Exchange
  • NRIX Nasdaq
  • CRSR Nasdaq
  • Market Cap
  • NRIX 970.1M
  • CRSR 1.0B
  • IPO Year
  • NRIX 2020
  • CRSR 2020
  • Fundamental
  • Price
  • NRIX $11.64
  • CRSR $9.30
  • Analyst Decision
  • NRIX Strong Buy
  • CRSR Buy
  • Analyst Count
  • NRIX 16
  • CRSR 5
  • Target Price
  • NRIX $29.56
  • CRSR $9.80
  • AVG Volume (30 Days)
  • NRIX 978.7K
  • CRSR 469.4K
  • Earning Date
  • NRIX 07-09-2025
  • CRSR 08-07-2025
  • Dividend Yield
  • NRIX N/A
  • CRSR N/A
  • EPS Growth
  • NRIX N/A
  • CRSR N/A
  • EPS
  • NRIX N/A
  • CRSR N/A
  • Revenue
  • NRIX $88,381,000.00
  • CRSR $1,348,872,000.00
  • Revenue This Year
  • NRIX $34.87
  • CRSR $14.40
  • Revenue Next Year
  • NRIX N/A
  • CRSR $9.76
  • P/E Ratio
  • NRIX N/A
  • CRSR N/A
  • Revenue Growth
  • NRIX 41.86
  • CRSR N/A
  • 52 Week Low
  • NRIX $8.18
  • CRSR $5.60
  • 52 Week High
  • NRIX $29.56
  • CRSR $13.02
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 46.20
  • CRSR 49.20
  • Support Level
  • NRIX $11.13
  • CRSR $8.98
  • Resistance Level
  • NRIX $11.92
  • CRSR $9.76
  • Average True Range (ATR)
  • NRIX 0.77
  • CRSR 0.34
  • MACD
  • NRIX -0.15
  • CRSR -0.05
  • Stochastic Oscillator
  • NRIX 11.79
  • CRSR 36.96

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About CRSR Corsair Gaming Inc.

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.

Share on Social Networks: